美国狼疮的临床管理:一项基于理赔数据的分析
该研究利用EVERSANA理赔数据库,对美国三个狼疮队列(狼疮肾炎、系统性红斑狼疮、皮肤型狼疮)的诊断、检查、用药和专科就诊情况进行分析。结果显示,部分患者的诊断依据不明确,自身抗体检测和活检不常规,专科参与不普遍;与对照人群相比,被编码为狼疮的患者在编码前后一年内的实验室检测、非狼疮诊断、急诊就诊和费用均增加。作者认为,全科医疗社区对狼疮患者的评估与管理并未严格遵循专业学会推荐的指南。
要点
- 共识别狼疮肾炎28372例、系统性红斑狼疮82744例、皮肤型狼疮13920例。
- 三个队列的诊断依据不总是明确,自身抗体检测不常规、活检不常见、亚专科参与不普遍。
- 被编码为狼疮的患者在编码前后一年内实验室检测、非狼疮诊断、急诊就诊和费用均增加。
核心结论
- 作者认为,尽管部分患者诊断依据不明确,全科医疗社区对被编码为狼疮患者的评估与管理并未严格遵循专业学会推荐的指南。
研究设计与样本
- 基于EVERSANA理赔数据库的理赔数据分析,评估三个狼疮队列(狼疮肾炎、除外狼疮肾炎的系统性红斑狼疮、除外系统性红斑狼疮和狼疮肾炎的皮肤型狼疮)的诊断、操作、药物和医师专科。
- 患者识别基于狼疮特异性代码的出现,要求同一患者在六个月内两次获得狼疮相关ICD代码。
主要发现
- 通过ICD代码识别狼疮肾炎28372例、系统性红斑狼疮82744例、皮肤型狼疮13920例,并评估各组在编码前后一年内的诊疗过程。
- 三个狼疮队列的诊断依据不总是明确,狼疮临床特征不常获取,自身抗体检测不常规,活检不常见,亚专科参与不普遍。
- 获得狼疮代码前一年内实验室检测、非狼疮诊断、急诊就诊和费用显著增加,提示疾病识别存在不确定性。
- 这些患者在六个月内出现两次独立的狼疮编码事件,支持评估临床医生对狼疮诊断的持续或重复确认。
- 三个狼疮队列在实验室检测频率、亚专科诊疗、皮肤和肾脏活检及药物管理方面存在差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To understand the evaluation and management of patients coded with lupus in the broad clinical community in the United States. METHODS: Claims data for diagnoses, procedures, medications, and physician specialties were evaluated for three lupus cohorts [lupus nephritis (LN), systemic lupus erythematosus excluding LN (SLE), and cutaneous lupus erythematosus excluding SLE and LN (CLE)] using the EVERSANA claims databases. Identification of patients was based upon the occurrence of lupus-specific codes, with the requirement that a single patient receive a lupus-related ICD code twice within a six-month period. RESULTS: Using ICD codes, we were able to identify 28,372 patients coded with LN, 82,744 patients coded with SLE, and 13,920 patients coded with CLE, and subsequently evaluate the journey of patients in each group in the year before and after being coded as having a diagnosis of lupus. For the three lupus cohorts, the basis of diagnosis was not always apparent, as clinical features of lupus were not often obtained, autoantibody testing was not usual, biopsies were uncommon and subspecialty involvement was not routine. In addition, a significant increase in laboratory testing, non-lupus diagnoses, emergency department visits and cost during the year before receiving a lupus code suggested uncertainty in disease recognition. Nevertheless, these patients received two separate lupus coding events within a six-month period, supporting a sustained or repeated diagnosis of lupus by the evaluating clinicians. When compared, the three lupus cohorts differed with regard to frequency of laboratory testing, subspecialty care, skin and renal biopsies, and medication management. Moreover, there was an increase in the cost of care of patients coded with lupus compared to a reference patient population both during the year before and after being coded with a diagnosis of lupus. CONCLUSION: The data present a comprehensive report of the care of patients coded as having a diagnosis of lupus in the United States, including those outside of specialty centers. Despite the unclear basis of diagnosis in some patients, evaluation and management of patients coded as having a diagnosis of lupus in the general care community does not closely follow the recommended guidelines set forth by professional societies.
引用
- Kingsmore KM, Zent JM, Lipsky PE, et al. Clinical management of lupus in the United States: A claims-based analysis. Semin Arthritis Rheum. 2024. PMID: 38875804. doi:10.1016/j.semarthrit.2024.152472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。